A Study to Evaluate the Effect of Pharmacokinetics (PK) of Acalabrutinib and its Active Metabolite (ACP-5862) when Administered Alone and With Moderate CYP3A4 Inhibitors Fluconazole or Isavuconazole in Healthy Adult Participants

Trial Identifier: ACE-HV-114
Sponsor: Acerta Pharma BV
NCTID:: NCT05140096
Start Date: January 2020
Primary Completion Date: April 2020
Study Completion Date: April 2020
Condition: Healthy Volunteers

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
United States, Arizona Tempe, Arizona, United States, 85283